BioCatalystWatch
INABWorkspace / INAB / OverviewCompany library
Price
Market cap
Next catalystClinical update at ASH in December 2026; subject to additional capital and changeINB-100 — Phase 1 post-HSCT leukemia trial · Conference presentationSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

INB-100

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

INB-619

CD19

Upcoming / outlook

  • Timing and evidence

INB-619

CD19

Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

INB-619

CD19

Upcoming / outlook

  • Timing and evidence

INB-100

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

INB-619

CD19

Upcoming / outlook

Other pipelines

DRI

PreINDP1P2P3FilingApproved

History / paused

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

INAB SEC archive